Form 8-K - Current report:
SEC Accession No. 0001558370-25-009989
Filing Date
2025-08-01
Accepted
2025-08-01 16:30:12
Documents
12
Period of Report
2025-08-01
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K plx-20250801x8k.htm   iXBRL 8-K 36632
  Complete submission text file 0001558370-25-009989.txt   149553

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20250801.xsd EX-101.SCH 3671
3 EX-101.LAB plx-20250801_lab.xml EX-101.LAB 16016
4 EX-101.PRE plx-20250801_pre.xml EX-101.PRE 10761
14 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250801x8k_htm.xml XML 4816
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 251176591
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)